Carbidopa-Levodopa (Carbidopa/Levodopa) — Medicare Part D spending
Multiple manufacturers (14) · Rank #338 by total Part D spend · CMS data year 2023
Medicare Part D spent $125,111,276 on Carbidopa-Levodopa (Carbidopa/Levodopa) in 2023, the #338 drug by total Part D spending out of 3,598 drugs. That worked out to about $0.20 per dosage unit, $45 per claim and $233 per beneficiary, across 2,789,516 claims for 537,069 beneficiaries. Average spending per dosage unit fell -5.1% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Carbidopa-Levodopa (Carbidopa/Levodopa) spending at a glance (2023)
| Metric | Carbidopa-Levodopa (Carbidopa/Levodopa) |
|---|---|
| Total Part D spending (2023) | $125,111,276 |
| Total spending (2022) | $124,949,247 |
| Year-over-year change in total spending | +0.1% |
| Average spending per dosage unit (2023) | $0.20 |
| Change in spend per dosage unit (YoY) | -5.1% |
| Avg annual change per dosage unit (2019-2023 CAGR) | +0.1% |
| Average spending per claim (2023) | $45 |
| Average spending per beneficiary (2023) | $233 |
| Total claims (2023) | 2,789,516 |
| Beneficiaries (2023) | 537,069 |
| Total dosage units (2023) | 646,218,953 |
| Manufacturer(s) | Multiple manufacturers (14) |
| National rank by total spend (of 3,598 drugs) | #338 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $124,949,247 | $125,111,276 | +0.1% |
| Avg spend per dosage unit | $0.21 | $0.20 | -5.1% |
| Avg spend per claim | $46 | $45 | — |
| Avg spend per beneficiary | $240 | $233 | — |
| Total claims | 2,710,497 | 2,789,516 | — |
| Beneficiaries | 519,978 | 537,069 | — |
How Carbidopa-Levodopa compares with nearby drugs
Drugs with total Part D spending closest to Carbidopa-Levodopa (Carbidopa/Levodopa):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Carbidopa-Levodopa (Carbidopa/Levodopa) (this drug, #338) | $125,111,276 | $0.20 | -5.1% |
| Gilenya (Fingolimod HCl) (#336) | $125,490,483 | $356.52 | +6.4% |
| Skyrizi On-Body (Risankizumab-Rzaa) (#337) | $125,306,777 | $9,002.43 | +13.5% |
| Humulin 70/30 Kwikpen (Insulin NPh Hum/Reg Insulin Hm) (#339) | $124,346,168 | $25.46 | +0.4% |
| Iclusig (Ponatinib HCl) (#340) | $123,338,680 | $686.96 | +6.1% |
| Valacyclovir (Valacyclovir HCl) (#341) | $121,564,610 | $1.04 | -12.4% |
Frequently asked questions
How much does Medicare Part D spend on Carbidopa-Levodopa?
Medicare Part D spent $125,111,276 on Carbidopa-Levodopa (Carbidopa/Levodopa) in 2023 (the latest CMS data year), across 2,789,516 claims for 537,069 beneficiaries. That ranks #338 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Carbidopa-Levodopa?
In 2023, the weighted average Medicare Part D spending per dosage unit for Carbidopa-Levodopa (Carbidopa/Levodopa) was $0.20. Compared with 2022 it fell -5.1%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Carbidopa-Levodopa?
CMS attributes Carbidopa-Levodopa (Carbidopa/Levodopa) to Multiple manufacturers (14) in the 2023 Part D spending file. Average spending per claim was $45 and per beneficiary $233.
Is the Carbidopa-Levodopa figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20